BDTX Stock — Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc (BDTX)

Updated October 16, 2026.

BDTX is a Stock. Total return is -95.6% over the past 6.7 years, 251.8 points behind SPY at 156.2%.

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey inhibitors for genetically defined tumors, with its lead candidate silevertinib in Phase 2 trials for brain tumors and lung cancer, and additional programs targeting RAF, KRAS, NRAS, BRAF, and FGFR mutations in earlier development stages. As a pre-revenue biotech company, the security does not currently distribute to shareholders. The company appeals primarily to investors with high risk tolerance who seek exposure to early-stage drug development in oncology.

BDTX performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.6% over the past 6.7 years, 251.8 points behind SPY at 156.2%. Over the past year its total return — price change plus distributions reinvested — is -58.8%. Its deepest 1-year drawdown was 66.9%.

BDTX key facts

Asset type

Stock

Asset class

Equity

Inception date

01/30/2020

Distribution frequency

None

Last close

$1.72 (as of 2026-10-16)

Market cap

$98,559,051

Average volume

539751.0

Beta

3.325

Payout ratio

0.0%

Forward P/E

8.3333

EPS

$-0.74

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BDTX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 66.9%.

Who may consider BDTX — and who may not

It is a weaker fit for investors who need monthly cash flow (BDTX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BDTX

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions